120092-68-4

Basic information

• Product Name: Manidipine
• Synonyms: 2-(4-(diphenylmethyl)-1-piperazinyl)-ethyl methyl (-)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate;METHYL 2-(4-BENZHYDRYLPIPERAZIN-1-YL)ETHYL 2,6-DIMETHYL-4-(3-NITROPHENYL)-1,4-DIHYDROPYRIDINE-3,5-DICARBOXYLATE;MANIDIPINE;(4S)-1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic Acid 2-[4-(Diphenylmethyl)-1-piperazinyl]ethyl Methyl Ester
• CAS NO: 120092-68-4
• Molecular Formula: C35H38N4O6
• Molecular Weight: 610.7
• Product Categories: Chiral Reagents;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 120092-68-4.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 721.996 °C at 760 mmHg
• Flash Point: 390.449 °C
• Appearance: /
• Density: 1.232 g/cm³
• Vapor Pressure: 1.07E-20mmHg at 25°C
• Refractive Index: 1.6
• Storage Temp.: -20°C Freezer
• Solubility: DMSO (Slightly), Methanol (Slightly, Sonicated)
• CAS DataBase Reference: Manidipine(CAS DataBase Reference)
• NIST Chemistry Reference: Manidipine(120092-68-4)
• EPA Substance Registry System: Manidipine(120092-68-4)

Safety Data

• Hazardous Substances Data: 120092-68-4(Hazardous Substances Data)

Usage

Uses

(S)-Manidipine enantiomer. A dihydropyridine calcium channel blocker. Antihypertensive

InChI:InChI=1/C35H38N4O6/c1-24-30(34(40)44-3)32(28-15-10-16-29(23-28)39(42)43)31(25(2)36-24)35(41)45-22-21-37-17-19-38(20-18-37)33(26-11-6-4-7-12-26)27-13-8-5-9-14-27/h4-16,23,32-33,36H,17-22H2,1-3H3

Upstream product

• 99-61-6 3-nitro-benzaldehyde 
• 89226-49-3 2-(4-diphenylmethyl-1-piperazinyl)ethyl acetoacetate 
• 14205-39-1 methyl 3-aminocrotonate 
• 841-77-0 diphenylmethylpiperazine 
• 10527-64-7 1-diphenylmethyl-4-(2-hydroxyethyl)piperazine 
• 74936-72-4 5-methoxycarbonyl-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carboxylic acid 
• 76093-37-3 (4R)-1-ethoxymethyl-1,4-dihydro-5-methoxycarbonyl-2,6-dimethyl-4-(3-nitrophenyl)-3-pyridinecarboxylic acid 
• 89226-50-6 manidipine 
• 89226-75-5 Manidipine dihydrochloride 
• 76093-31-7 1-ethoxymethyl-1,4-dihydro-5-methoxycarbonyl-2,6-dimethyl-4-(3-nitrophenyl)-pyridine-3-carboxylic acid 
• 88712-56-5 methyl (R)-5-chlorocarbonyl-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carboxylate 
• 39562-17-9 methyl 2-(3-nitrophenylmethylene)acetoacetate 
• 90120-00-6 2-(4-diphenylmethyl-1-piperazinyl)ethyl 2-(3-nitrobenzylidene)acetoacetate 
• 76093-33-9 (R)-5-(methoxycarbonyl)-2,6-dimethyl-4-(m-nitrophenyl)-1,4-dihydropyridine-3-carboxylic acid 

Downstream Products

• 126451-47-6 (S)-Manidipine 

Relevant articles and documents

Preparation method of calcium ion channel antagonist manidipine

The invention discloses a preparation method of a calcium ion channel antagonist manidipine. The method comprises the following steps: 1) dissolving methyl beta-aminocrotonate, carring out reaction on the methyl beta-aminocrotonate and 1-diphenylmethyl-4-(2-hydroxyethyl)piperazidine in the presence of a catalyst in a 50-70-DEG C organic solvent to generate diphenylmethylpiperazinylethyl beta-aminocrotonate; and 2) adding the diphenylmethylpiperazinylethyl beta-aminocrotonate and methyl 2-(3-nitrobenzylidene)acetoacetate into a reactor filled with an alcohol solvent, carrying out gradient to 75 DEG C, continuing heating to reflux, refluxing for 3-5 hours, reacting completely to obtain a manidipine crude product, cooling to 0 DEG C, cooling over night, filtering, and recrystallizing to obtain the manidipine pure product, wherein the alcohol solvent is anhydrous ethanol. The method has the advantages of simple preparation process, short reaction period, fewer generated byproducts and simple after-treatment; the yield of the prepared product can reach 90% or above; and the method is suitable for industrial production.

Polymorphic Forms of Manidipine

The invention relates to various new polymorphic forms of manidipine and pharmaceutically acceptable salts thereof. The invention also relates to processes for the preparation of the polymorphic forms of manidipine and pharmaceutically acceptable salts thereof.

THERAPY FOR COMPLICATIONS OF DIABETES

A method for enhancing glycemic control and/or insulin sensitivity in a human subject having diabetic nephropathy and/or metabolic syndrome comprises administering to the subject a selective endothelin A (ETA) receptor antagonist in a glycemic control and/or insulin sensitivity enhancing effective amount. A method for treating a complex of comorbidities in an elderly diabetic human subject comprises administering to the subject a selective ETA receptor antagonist in combination or as adjunctive therapy with at least one additional agent that is (i) other than a selective ETA receptor antagonist and (ii) effective in treatment of diabetes and/or at least one of said comorbidities other than hypertension. A therapeutic combination useful in such a method comprises a selective ETA receptor antagonist and at least one antidiabetic, anti-obesity or antidyslipidemic agent other than a selective ETA receptor antagonist.